Specialized Medical Company (SMC Healthcare) announces its interim condensed consolidated financial results for the period ending on 2026-06-30 (Six Months)

SMC Healthcare achieved a 24.2% year-on-year increase in net profit to $45.2 million for Q2 2026, supported by revenue growth of 5.7% to $401.3 million as patient activity ramped up following seasonal impacts in the previous quarter.
Profitability was driven by an expansion in EBITDA margins to 20.6% (up from 19.6% in Q2 2025), resulting from a shift toward higher-margin acute care services, lower finance costs, and improved operating efficiency in G&A and marketing expenses.
Operational growth included a 10.9% increase in outpatient visits and a 12.8% rise in inpatient visits YoY, further supported by the opening of five additional clinics at SMC 1 during the second quarter.
The company signed a significant 15-year Public-Private Partnership (PPP) contract in July 2026 with an estimated value of $3.8 billion to operate the 150-bed SABIC Behavioral Care Specialist Hospital, with operational commencement targeted for Q2 2027.

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	401,327	379,813	5.664	380,674	5.425
Gross Profit (Loss)	100,127	98,564	1.585	90,968	10.068
Operational Profit (Loss)	55,533	48,578	14.317	41,083	35.172
Net Profit (Loss) Attributable to Shareholders of the Issuer	45,179	36,362	24.247	32,550	38.798
Total Comprehensive Income Attributable to Shareholders of the Issuer	43,730	35,990	21.505	31,101	40.606
All figures are in (Thousands) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Sales/Revenue	782,002	748,209	4.516
Gross Profit (Loss)	191,095	186,981	2.2
Operational Profit (Loss)	96,616	89,253	8.249
Net Profit (Loss) Attributable to Shareholders of the Issuer	77,729	66,002	17.767
Total Comprehensive Income Attributable to Shareholders of the Issuer	74,831	65,258	14.669
Total Shareholders Equity (after Deducting Minority Equity)	982,685	992,354	-0.974
Profit (Loss) per Share	0.31	0.26
All figures are in (Thousands) Saudi Arabia, Riyals

Element List	Amount	Percentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value	-	-
All figures are in (Thousands) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is	The Group’s revenue for the second quarter of 2026 reached SAR 401.3 million, representing YoY growth of 5.7%. This performance was driven by increased outpatient clinic activity, supported by the continued ramp-up of the new clinics opened during 2025. Revenue growth was further supported by higher inpatient revenue driven by the increased outpatient activity.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	Revenue growth and the improved business mix translated into stronger profitability and margin expansion, with the Group’s net profit for the second quarter of 2026 reaching SAR 45.2 million, representing YoY growth of 24.2%. The net profit margin also expanded to 11.3%, compared with 9.6% in the corresponding period of the previous year. This improvement was driven by revenue growth, enhanced operating efficiency, including lower G&A and marketing expenses, and reduced finance costs. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) reached SAR 82.8 million, with an EBITDA margin of 20.6%, compared with 19.6% in the second quarter of 2025.
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is	The Group’s revenue increased by 5.4% compared with the first quarter of 2026, supported by higher patient volumes following the seasonal impact of Ramadan, the Eid vacation, and the extended school break. The continued ramp-up of the new clinics and the growing contribution from the higher-margin acute care mix, further supported the Group’s operating performance.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is	The Group’s net profit for the second quarter of 2026 reached SAR 45.2 million, representing quarter-on-quarter growth of 38.8% compared with the first quarter of 2026. This growth was driven by higher patient volumes following the Q1 seasonal impact of Ramadan, the Eid vacation, and the extended school break, alongside an improvement in the operating costs. These factors, together with the continued ramp-up of the new clinics opened during 2025 and an improved business mix, contributed to stronger revenue and higher profit margins.
The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is	The Group’s revenue for the first six months of 2026 reached SAR 782.0 million, representing YoY growth of 4.5% compared with SAR 748.2 million in the corresponding period of 2025. This growth was driven by increased outpatient clinic activity and the growing contribution from the new clinics opened progressively during 2025 as they continued to ramp up operations. Revenue growth was further supported by higher inpatient revenue driven by the increased outpatient activity.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is	Net profit increased 17.8% YoY to SAR 77.7 million in the first six months of 2026, compared with SAR 66.0 million in the corresponding period of 2025. This performance was driven by the expansion of the clinic network, improved operating efficiency, higher contribution from higher-margin inpatient services, disciplined operating expense management, and lower finance costs, with net profit growth exceeding revenue growth during the period.
Statement of the type of external auditor's report	Unmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)	NA
Reclassification of Comparison Items	Certain figures for the comparison period have been reclassified to conform to the presentation in the current period.‎
Additional Information	NA
Attached Documents	Attached Documents